research Rivaroxaban-induced hair loss
Rivaroxaban may cause hair loss.
Search
for
Sort by
Research
480-510 / 1000+ results research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research Эффективность комбинированных оральных контрацептивов у женщин с синдромом поликистозных яичников
Both finasteride and drospirenone effectively manage PCOS symptoms, but drospirenone is more effective in reducing ovarian volume and androgen levels.
research Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: A legitimate approach
New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Novel small molecules downregulate CDK1 expression and inhibit Wnt/β-catenin signaling in cutaneous squamous cell carcinoma by targeting its distinct tumor-specific cellular landscape
Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
research NEW PROPRIETARY BRANDS: Gabapentin
Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
Baricitinib is effective and safe for treating severe alopecia areata.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research Evaluation of efficacy, safety, and reversibility of combination regimen of cyproterone acetate and testosterone buciclate in bonnet monkey
The right dosage of CPA and TB can work as a safe and reversible male contraceptive in monkeys.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
research [Acceptability, tolerance and quality of life impact of cyproterone acetate treatment in female hirsutism. Comparison of 2 protocols in combination with oral or transdermal estradiol].
Cyproterone acetate with estradiol improved women's self-confidence and emotional well-being without a difference between oral or transdermal methods, but younger women preferred the oral method.
research Niosomal versus cubosomal gels of cetirizine hydrochloride: Cost-effective permeation enhancement for potential transdermal application
Cubosomal gels enhance skin absorption of cetirizine better than niosomal gels.
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Ritlecitinib was generally well tolerated in children with alopecia areata.
research Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation
research [Contraceptive methods for adolescents].
Oral contraceptives are generally recommended for healthy young girls, but specific types may vary based on individual health conditions and barrier methods are less popular among adolescents.
research Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Myo-inositol may be more effective than metformin for inducing ovulation in women with PCOS.
research Determination of rat 5α-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines
New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
research Sex Hormones and Related Compounds, Including Hormonal Contraceptives
Hormonal contraceptives and related compounds can increase health risks like thrombosis and affect sexual function.
research Corticotropin releasing factor-1 receptor antagonism associated with favorable outcomes of male reproductive health biochemical parameters
Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
research Potassium channel openers: therapeutic potential in cardiology and medicine
Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
research Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
Sonidegib and vismodegib have different side effects and reporting patterns.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research Finasteride in polycythaemia
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.